NY-AQARA
23.3.2023 09:01:30 CET | Business Wire | Press release
Aqara, a leading provider of smart home products, announces the wide availability of the Company’s first smart video doorbell, the G4, on global markets. This 1080p doorbell features wide compatibility with third-party smart home platforms such as Apple Home, Alexa and Google Home, and it is equipped with on-device AI to enable local facial recognition alerts and automation. Together with the Company’s indoor cameras, the video doorbell G4 helps users keep an eye on their homes, families and visitors anytime, anywhere. The device is now available on Aqara’s Amazon brand stores in both North America (US, Canada) and Europe (France, Germany, Italy, Spain, UK) as well as via selective Aqara retailers worldwide1.
Similar to Aqara’s Camera Hub G3, the Aqara Smart Video Doorbell G4 features AI-based facial recognition, which is executed locally on device for faster response and privacy protection. Moreover, facial recognition of the doorbell can be used as an automation trigger, allowing users to set up customized home automation for different families and visitors. For example, the welcome home scene will be activated when the G4 recognizes a family member coming home. Or in the case that it detects the postman, the doorbell will play a pre-recorded message. When connected to other Aqara devices, the G4 doorbell can also be a strong addition to the Aqara Home alert system as it not only monitors the activities around the front porch but also lets out a loud siren in case of home intrusion and other emergencies.
Apart from the Aqara ecosystem, the G4 doorbell also supports major third-party smart home platforms including Apple Home, Amazon Alexa and Google Home. This device is one of the few battery-powered video doorbells on the market that support Apple’s HomeKit Secure Video as well as the local streaming to Amazon and Google smart displays. Moreover, Aqara anticipates adding the support of the new Matter standard to the G4 via a future OTA (over the air) update2.
With two color variants, Shadow Gray and Black, the video doorbell G4 is designed to fit into most home environments. It supports both wireless and wired installation and can use a pack of 6 AA batteries that lasts about 4 months3. The doorbell offers adjustable sensitivity, configurable motion detection and even a power saving mode for users who live in a high traffic area to extend the battery life. Alternatively, users can opt to wire the G4 doorbell to an AC/DC transformer for 24/7 recording4, and use the battery pack as a back-up power source. Additionally, the G4’s chime repeater, which is equipped with a 95 dB speaker, houses a Type-C port, and allows more flexibility for users to place the chime repeater indoors.
Users of the Video Doorbell G4 can store video footage locally or on the cloud via iCloud or Aqara platform5. Aqara offers a subscription-free cloud storage of up to 7 days of critical event clips such as motion detection, facial recognition, doorbell ring and tamper alerts. Users can also choose to save video footage locally using a microSD card (up to 512 GB)6, which is housed in the indoor chime repeater. Finally, videos can also be stored via SMB NAS for added flexibility and security7.
For more details of the G4 video doorbell, please visit our website.
- Product availability may vary among different retail channels, and could be updated all the time. It’s recommended to check with the regional retailer(s) for real time availability.
- Matter support is not available by the time of launch.
- Based on assumption of 35 device wake-ups and one 6-second event video recording per day. The actual battery life may vary, depending on multiple factors including device usage, battery capacity, ambient temperature, etc.
- A 12-24V AC or 8-24V DC transformer is required. Both a wired installation and the use of a microSD card are required for 24/7 recording.
- iCloud or other supported cloud storage is not included, and should be controlled separately via the respecting app.
- The microSD card is not included.
- SMB NAS support may be unavailable by the time of product launch.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230323005016/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
